Details of the Drug

General Information of Drug (ID: DMT3D5I)

Drug Name
Aflibercept
Synonyms Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
Indication
Disease Entry ICD 11 Status REF
Central retinal vein occlusion with macular edema N.A. Approved [1]
Diabetic macular edema 9B71.02 Approved [2]
Exudative age-related macular degeneration 9B78.3Z Approved [3]
Metastasis from malignant tumor of colon N.A. Approved [4]
Metastatic colorectal cancer 2B91 Approved [5]
Sequence
SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDS
RKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKL
VLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQ
GLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPG
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.02 mg/L []
Elimination
The drug is excreted via kidney and liver []
Half-life
The concentration or amount of drug in body reduced by one-half in 7.13 days [6]
Metabolism
The drug is metabolized via proteolysis into smaller peptides and amino acids []
Vd
The volume of distribution (Vd) of drug is 6 L []
Cross-matching ID
DrugBank ID
DB08885
TTD ID
D0C9ET
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [5]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [5]
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Central retinal vein occlusion with macular edema
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Aflibercept (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Aflibercept and Tecfidera. Multiple sclerosis [8A40] [7]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Aflibercept and Siponimod. Multiple sclerosis [8A40] [8]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Aflibercept and Ocrelizumab. Multiple sclerosis [8A40] [9]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Aflibercept and Ozanimod. Multiple sclerosis [8A40] [10]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Aflibercept when combined with Anthrax vaccine. Sepsis [1G40-1G41] [11]

References

1 A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
2 Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
3 Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
4 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e323-e328.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]